Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

Phase 2

Terminated

Conditions: Esophageal Cancer
Adenocarcinoma of the Esophagus
Squamous Cell Carcinoma

Interventions: Drug: OncoGel (Paclitaxel gel)
Drug: cisplatin
Drug: 5-FU
Radiation: radiation therapy
Procedure: esophageal resection

First Posted Date: 2007-12-13

Last Posted Date: 2022-06-22

Lead Sponsor: Boston Scientific Corporation

Target Recruit Count: 137

Registration Number: NCT00573131

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Indiana University Medical Center, Indianapolis, Indiana, United States

and more 17 locations

Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer

Phase 2

Withdrawn

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Biological: cetuximab
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2007-12-12

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Registration Number: NCT00571740

Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma

Phase 2

Terminated

Conditions: Loco-regional Esophageal Cancer

Interventions: Drug: Bevacizumab
Drug: Paclitaxel
Drug: Cisplatin
Drug: 5-Fluorouracil
Radiation: Radiation Therapy
Procedure: Esophagectomy

First Posted Date: 2007-12-11

Last Posted Date: 2016-05-26

Lead Sponsor: University of Michigan Rogel Cancer Center

Target Recruit Count: 6

Registration Number: NCT00570531

Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents

Phase 2

Completed

Conditions: Nasopharyngeal Neoplasms
Carcinoma

Interventions: Drug: docetaxel
Drug: cisplatin
Drug: 5-fluorouracil

First Posted Date: 2007-11-30

Last Posted Date: 2015-07-30

Lead Sponsor: Sanofi

Target Recruit Count: 75

Registration Number: NCT00565448

Locations: 🇲🇦
Investigational Site Number 504003, Rabat, Morocco
🇵🇭
Investigational Site Number 608002, Quezon City, Philippines
🇧🇷
Investigational Site Number 076002, Rio De Janeiro, Brazil

and more 23 locations

Benefit of Adding Chemotherapy for Advance Nasopharyngeal Carcinoma (T1-4N2-3M0)

Not Applicable

Conditions: Nasopharyngeal Neoplasms
Carcinoma, Squamous Cell

First Posted Date: 2007-11-26

Last Posted Date: 2010-07-07

Lead Sponsor: Hospital Authority, Hong Kong

Target Recruit Count: 340

Registration Number: NCT00563927

Locations: 🇨🇳
Pamela Youde Nethersole Eastern Hospital, Hong Kong, China
🇨🇳
Tuen Mun Hospital, Hong Kong, China
🇨🇳
Queen Elizabeth Hospital, Hong Kong, China

and more 1 locations